NCT02143635View on ClinicalTrials.gov

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

PHASE1CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

July 7, 2014

Primary Completion Date

June 20, 2017

Study Completion Date

June 9, 2020

Conditions
Advanced Solid and Hematological TP53wt Tumors
Interventions
DRUG

HDM201

DRUG

ancillary treatment

Trial Locations (15)

10017

Memorial Sloan Kettering Onc. Dep, New York

10041

Novartis Investigative Site, Taipei

45147

Novartis Investigative Site, Essen

60590

Novartis Investigative Site, Frankfurt

69373

Novartis Investigative Site, Lyon

75010

Novartis Investigative Site, Paris

97080

Novartis Investigative Site, Würzburg

169610

Novartis Investigative Site, Singapore

02215

Dana Farber Cancer Institute SC-6, Boston

650-0017

Novartis Investigative Site, Kobe

104 0045

Novartis Investigative Site, Chuo Ku

1066 CX

Novartis Investigative Site, Amsterdam

3584CX

Novartis Investigative Site, Utrecht

08035

Novartis Investigative Site, Barcelona

08036

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT02143635 - Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt | Biotech Hunter | Biotech Hunter